Esperion Therapeutics, Inc.
NASDAQ:ESPR · NASDAQ Global Market
+$0.00 today
Vol 17.00M · Avg 12.29M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $156.2M |
| Receivables | $132.4M |
| Inventory | $104.2M |
| Other Current | $66.7M |
| Total Current Assets | $459.5M |
| PP&E (Net) | $3.0M |
| Intangible Assets | $56.0K |
| Total Non-current Assets | $3.1M |
| Total Assets | $462.5M |
Analysis
Selected assets total $462.5M for Latest. The largest visible component is Cash & Equivalents at $156.2M, about 33.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $167.9M +16.0% | $144.8M +76.0% | $82.2M -34.1% | $124.8M -40.3% | $208.9M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 -100.0% | $42.1M -16.6% | $50.4M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $140.2M +74.9% | $80.1M +65.3% | $48.5M +43.8% | $33.7M +47.1% | $22.9M | $533.8M | $399.4M | -$1.7B |
| Inventory | $105.1M +11.3% | $94.5M +44.0% | $65.6M +86.4% | $35.2M +2.3% | $34.4M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $4.5M -75.0% | $18.0M +299.8% | $4.5M -54.3% | $9.9M -11.7% | $11.2M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $462.6M +36.9% | $338.0M +68.1% | $201.1M -18.5% | $246.7M -25.0% | $329.0M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $3.3M -43.5% | $5.8M +23.4% | $4.7M +289.6% | $1.2M -53.2% | $2.6M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $56.0K +0.0% | $56.0K +0.0% | $56.0K +0.0% | $56.0K +0.0% | $56.0K | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $417.9M | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | -$123.1M | $0 | $0 | $0 -100.0% | $50.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $298.0M +5018.2% | $5.8M +23.1% | $4.7M +276.7% | $1.3M -97.6% | $52.6M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $465.9M +35.5% | $343.8M +67.1% | $205.8M -17.0% | $247.9M -35.0% | $381.6M | $13.3B | $11.9B | $10.6B |
| Account Payables | $65.1M +26.0% | $51.6M +62.8% | $31.7M +37.7% | $23.0M +31.2% | $17.6M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $89.7M -12.2% | $102.2M +193.3% | $34.8M +38.5% | $25.1M +98.2% | $12.7M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $34.5M +304.8% | $8.5M -66.5% | $25.4M +624.3% | $3.5M -38.3% | $5.7M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $9.8M -22.8% | $12.7M -74.1% | $49.2M +443.9% | $9.1M +2.8% | $8.8M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $300.8M +22.2% | $246.2M +57.6% | $156.2M +69.2% | $92.3M +25.8% | $73.4M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $457.6M -5.4% | $483.7M -3.6% | $501.5M +93.0% | $259.9M +0.6% | $258.3M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 -100.0% | $634.0K | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $8.7M -96.4% | $246.0M +2.5% | $239.9M +9.6% | $218.8M -10.9% | $245.7M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $467.0M -4.0% | $486.3M -3.6% | $504.6M +5.2% | $479.4M -5.1% | $505.2M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $767.9M +4.8% | $732.5M +10.9% | $660.8M +15.6% | $571.7M -1.2% | $578.5M | $14.7B | $3.7B | $9.6B |
| Common Stock | $245.0K +25.0% | $196.0K +66.1% | $118.0K +57.3% | $75.0K +23.0% | $61.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.6B -1.4% | -$1.6B -3.3% | -$1.5B -15.6% | -$1.3B -21.1% | -$1.1B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 +100.0% | -$2.0K +93.5% | -$31.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | -$302.0M +22.3% | -$388.7M +14.6% | -$455.0M -40.5% | -$323.8M -64.4% | -$196.9M | $9.1B | $7.7B | $3.3B |
| Total Debt | $548.0M -7.3% | $591.2M +9.3% | $540.9M +107.3% | $260.9M +0.3% | $260.2M | $724.2M | $410.6M | $399.4M |
| Net Debt | $380.1M -14.9% | $446.5M -2.7% | $458.7M +236.9% | $136.2M +165.4% | $51.3M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Absci Corporation
NASDAQ:ABSI
$1.14B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$991.47M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$801.41M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$462.58M
REGENXBIO Inc.
NASDAQ:RGNX
$417.20M
Emergent BioSolutions Inc.
NYSE:EBS
$411.48M
Orthofix Medical Inc.
NASDAQ:OFIX
$373.16M
SNDL Inc.
NASDAQ:SNDL
$368.17M
SIGA Technologies, Inc.
NASDAQ:SIGA
$308.05M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ESPR have?
Esperion Therapeutics, Inc. (ESPR) reported $167.85M in cash and equivalents in fiscal 2025.
How much debt does ESPR carry?
Esperion Therapeutics, Inc. (ESPR) reported $548.00M of total debt, with net debt of $380.15M.
Explore More
Continue the stock analysis
Jump to another research area for this company.